EDG2抗体;EDG2 Antibody—艾普蒂

+ +

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of EDG2 expression in A375 cell lysate.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

The EDG2 antibody targets the Endothelial Differentiation Gene 2 (EDG2), also known as lysophosphatidic acid receptor 1 (LPA₁), a G protein-coupled receptor (GPCR) that binds lysophosphatidic acid (LPA). LPA is a bioactive phospholipid involved in diverse physiological processes, including cell proliferation, migration, and survival, as well as pathological conditions like fibrosis, cancer, and inflammation. EDG2/LPA₁ is widely expressed in tissues such as the brain, cardiovascular system, and immune cells, playing critical roles in embryonic development, neural signaling, and tissue repair.

EDG2 antibodies are essential tools for studying LPA₁ expression, localization, and function in vitro and in vivo. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate receptor dynamics in disease models. Researchers also employ EDG2-blocking antibodies to dissect LPA-mediated signaling pathways (e.g., via Rho, MAPK, or PLC) and evaluate therapeutic potential in disorders driven by aberrant LPA signaling. For instance, EDG2 antibodies have been applied in cancer research to explore LPA₁'s role in tumor metastasis or in fibrosis studies to assess its contribution to extracellular matrix remodeling.

The development of EDG2-targeted therapies, including small-molecule inhibitors, underscores the receptor's clinical relevance. However, antibodies remain vital for mechanistic studies and biomarker validation, bridging basic research and translational applications.